Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the DREAMM-14 trial (NCT05064358), which is evaluating different dosing regimens of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM), with the main aim of minimizing the ocular toxicity associated with this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.